{
  "abstract": "Introduction Iron deficiency (ID) is prevalent among patients with heart failure (HF) and is associated with poor clinical outcomes, including reduced quality of life, increased symptom burden, and elevated hospitalisation and mortality rates. Notably, even in the absence of anaemia, ID negatively impacts exercise tolerance and functional capacity. Intravenous (IV) iron therapy has been shown to improve these parameters. The 2023 European Society of Cardiology Heart Failure Guidelines recommend IV iron for symptomatic patients with heart failure with reduced ejection fraction and mildly reduced ejection fraction.Methods This observational study aims to evaluate the recurrence of ID following IV iron therapy. Patients were reassessed for ferritin, transferrin saturation (Tsat), and haemoglobin (Hb) levels at 3 to 12 months post-treatment. ID was defined as absolute (ferritin < 100 μg/L) or functional (ferritin 100–199 μg/L with Tsat < 20%). Anaemia was defined as Hb < 12 g/dL in females and < 13 g/dL in males.Results Among 70 patients evaluated, 74.2% (n=52) achieved complete resolution of absolute iron deficiency (ID), while 12.9% (n=9) transitioned to functional ID. Persistent absolute ID was observed in 8.6% (n=6); three had stage IIIb or higher chronic kidney disease (CKD), and one had a history of malignancy. Additionally, 4.3% (n=3) improved from functional ID to normal iron indices. Hemoglobin (Hb) levels improved in 69% (n=48), including nine who fully corrected their anaemia. Two patients developed new-onset anaemia despite adequate iron repletion, both with comorbidities—autoimmune disease and alcohol misuse. Overall, mean Hb increased by 0.44 g/dL, serum ferritin by 361 μg/L, and transferrin saturation (Tsat) by 10% ( figure 1), (figure 2).Conclusion IV iron therapy improves iron parameters and Hb in HF patients. However, a subset may experience persistent or recurrent ID, underscoring the need for individualised follow-up. Comorbidities should be considered in patients not responding as expected.Abstract 50 Figure 1Iron deficiency recurrenceAbstract 50 Figure 2Anaemia recurrence",
  "authors": [
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "G Bruno"
    },
    {
      "affiliations": [
        "UCD, DUBLIN, Ireland"
      ],
      "name": "C Kazan"
    },
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "F Fabamwo"
    },
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "D McCaffrey"
    },
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "C Mahon"
    },
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "M Barrett"
    },
    {
      "affiliations": [
        "SVUH, DUBLIN, Ireland"
      ],
      "name": "K McDonald"
    }
  ],
  "title": "50 Recurrent iron deficiency after intravenous iron therapy in heart failure patients: an observational study",
  "uid": "6e317149-c887-5d96-88e2-ee250873d53c"
}